Efficacy, safety, and economy of tenofovir in the treatment of chronic hepatitis B from different manufacturers under the National Procurement Policy: a multicentre, prospective, real-world study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036417

Enrollment

Unknown

Registered

2020-08-23

Start date

2020-08-12

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

experimental group:Medication

control group:Medication

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of chronic hepatitis B in the Guidelines for The Prevention and Treatment of Chronic Hepatitis B (2019 edition) [2] and need antiviral treatment; (2) Aged 18 to 65 years; (3) Volunteer to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Patients with other types of liver disease, HIV, liver cancer or decompensated liver disease; (3) persons with a history of abuse of psychotropic substances and unable to quit or with mental disorders; (4) The investigator's judgment of other circumstances that may affect the conduct of the clinical study and the determination of the study results.

Design outcomes

Primary

Measure	Time frame
HBV-DNA;HBeAg;ALT;	—

Countries

China

Contacts

Public ContactWeihua Yin

the First People's Hospital of Kunshan

676639883@qq.com+86 15151669578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026